Vascular Biogenics Ltd

+0.01 (+7.30%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)11.92M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.13 Million
Adjusted EPS-$0.11
See more estimates
10-Day MA$0.16
50-Day MA$0.21
200-Day MA$1.21
See more pivots

Vascular Biogenics Ltd Stock, NASDAQ:VBLT

8 HaSatat Street, Modiâ??in, Jerusalem 7178106
Phone: +972.8.9935000
Number of Employees: 41


Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.